Search results
Moleculin Announces Formation of Scientific Advisory Board to Support Development of Annamycin
KTLA-TV Los Angeles· 14 hours agoMartin Tallman. Dr. Tallman is an internationally renowned clinical investigator whose discoveries have fueled the progress of leukemia-targeting therapies, most recently ...
MorphoSys Says Novartis Deal Progressing Steadily Despite Safety Concerns Over Bone Marrow Cancer...
Benzinga· 2 days agoMorphoSys AG MOR is reportedly facing a burgeoning safety concern surrounding pelabresib, an...
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Holdings Cut by Russell Investments Group Ltd.
ETF DAILY NEWS· 11 hours agoRussell Investments Group Ltd. lowered its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Free Report) by 84.5% during the fourth quarter, according to its most recent Form 13F filing with ...
Curis to Release First Quarter 2024 Financial Results and Hold Conference Call on May 7, 2024
Morningstar· 2 days agoCuris, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company ...
Cullinan Oncology, Inc. (NASDAQ:CGEM) Sees Large Growth in Short Interest
ETF DAILY NEWS· 3 days agoCullinan Oncology, Inc. (NASDAQ:CGEM – Get Free Report) was the recipient of a large increase in short interest in April. As of April 15th, there was short interest totalling 1,680,000 shares ...
Secondary cancer: Why breast cancer survivors have a higher risk
Medical News Today· 7 days agoThe age of cancer diagnosis appears to affect second cancer risk, especially for women, as does economic status. In it, researchers from the University of Cambridge in England report that women ...
Ayala Pharmaceuticals (NASDAQ:ADXS) Earns Sell Rating from Analysts at StockNews.com
ETF DAILY NEWS· 7 days agoStockNews.com initiated coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS – Free Report) in a research note released on Wednesday. The firm issued a sell rating on the stock. Ayala Pharmaceuticals ...
Brokerages Set Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Price Target at $195.08
ETF DAILY NEWS· 1 day agoShares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the thirteen ratings firms that are currently covering the ...
Affimed (NASDAQ:AFMD) Short Interest Update
ETF DAILY NEWS· 3 days agoAffimed (NASDAQ:AFMD – Get Free Report) was the target of a significant increase in short interest in April. As of April 15th, there was short interest totalling 219,400 shares, an increase ...
Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market
Investor's Business Daily· 7 days agoActinium is working on a radiopharmaceutical-based treatment foracute myeloid leukemia. But more...